• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    23 Stocks Moving in Tuesday's Pre-Market Session

    1/18/22 6:30:09 AM ET
    $AVGR
    $BBIG
    $CEI
    $CPOP
    Medical/Dental Instruments
    Health Care
    Recreational Games/Products/Toys
    Consumer Discretionary
    Get the next $AVGR alert in real time by email

    Gainers

    • ION Geophysical Corporation (NYSE:IO) shares rose 52.9% to $1.30 in pre-market trading after the company reported forbearance and amendment related to its revolving credit agreement, forbearance agreement related to its senior secured second priority notes due 2025. The company also reported preliminary Q4 revenues of $40 million, representing a 45% year-over-year surge.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) rose 21.7% to $25.40 in pre-market trading after jumping 27% on Friday.
    • Pluristem Therapeutics Inc. (NASDAQ:PSTI) rose 17.6% to $2.27 in pre-market trading after jumping 10% on Friday. Pluristem Therapeutics and Tnuva recently announced a collaboration to establish a cultured food platform.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares rose 11.1% to $0.94 in pre-market trading. Surgalign Holdings recently acquired 'significant equity interest' in Intenural Networks.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) rose 10.1% to $4.48 in pre-market trading following a 15% surge on Friday.
    • Pop Culture Group Co., Ltd (NASDAQ:CPOP) rose 9.3% to $1.88 in pre-market trading after declining around 3% on Friday.
    • Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) rose 8.6% to $0.71 in pre-market trading. Idera Pharmaceuticals was granted U.S. Patent #11,224,611 'Immune modulation with TLR9 agonists for cancer treatment.'
    • Avinger, Inc. (NASDAQ:AVGR) rose 6.8% to $0.3330 in pre-market trading. Avinger recently reported closing of $7.6 million registered direct offering.
    • Cenntro Electric Group Limited (NASDAQ:CENN) rose 5.7% to $3.36 in pre-market trading after jumping around 22% on Friday.
    • East Stone Acquisition Corporation (NASDAQ:ESSC) rose 4.1% to $16.17 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Check out these big penny stock gainers and losers

    Losers

    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares fell 46.1% to $0.2895 in pre-market trading after the company reported a proposed underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares.
    • Splash Beverage Group, Inc. (NASDAQ:SBEV) shares fell 18.4% to $3.41 in pre-market trading after jumping around 119% on Friday.
    • Molecular Partners AG (NASDAQ:MOLN) shares fell 16.1% to $26.77 in pre-market trading. Molecular Partners finalized license agreement with Novartis for Ensovibep for COVID-19.
    • OneSmart International Education Group Limited (NYSE:ONE) fell 14.4% to $0.16 in pre-market trading after declining over 5% on Friday..
    • Skylight Health Group Inc. (NASDAQ:SLHG) shares fell 11% to $0.89 in pre-market trading.
    • Retail Value Inc. (NYSE:RVI) fell 10.4% to $5.76 in pre-market trading.
    • vTv Therapeutics Inc. (NASDAQ:VTVT) fell 10.1% to $0.79 in pre-market trading.
    • Unilever PLC (NYSE:UL) fell 9.9% to $48.96 in pre-market trading. GlaxoSmithKline received three proposals from Unilever for its Consumer business. However, Glaxo rejected all three offers from the company.
    • Mechel PAO (NYSE:MTL) shares fell 9.8% to $2.85 in pre-market trading.
    • Camber Energy, Inc. (NYSE:CEI) shares fell 8.6% to $0.6850 in pre-market trading. Camber Energy recently received a letter from the NYSE American.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) fell 8.2% to $3.01 in pre-market trading after declining 5% on Friday.
    • Poshmark, Inc. (NASDAQ:POSH) shares fell 8.1% to $15.61 in pre-market trading.
    • IZEA Worldwide, Inc. (NASDAQ:IZEA) fell 7.9% to $1.17 in pre-market trading. IZEA recently highlights release of latest research initiative 'Influencing the Metaverse.'
    Get the next $AVGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVGR
    $BBIG
    $CEI
    $CPOP

    CompanyDatePrice TargetRatingAnalyst
    Unilever PLC
    $UL
    2/9/2026Buy → Hold
    Deutsche Bank
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    Unilever PLC
    $UL
    1/8/2026$71.00Outperform → Neutral
    BNP Paribas Exane
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    Unilever PLC
    $UL
    12/15/2025$60.10Overweight
    Morgan Stanley
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    Unilever PLC
    $UL
    5/29/2025$73.00Outperform
    BNP Paribas Exane
    More analyst ratings

    $AVGR
    $BBIG
    $CEI
    $CPOP
    SEC Filings

    View All

    Mainz Biomed N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MAINZ BIOMED N.V. (0001874252) (Filer)

    2/10/26 5:00:21 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Pop Culture Group Co. Ltd

    EFFECT - Pop Culture Group Co., Ltd (0001807389) (Filer)

    2/10/26 12:15:17 AM ET
    $CPOP
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Splash Beverage Group Inc. (NV) filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SPLASH BEVERAGE GROUP, INC. (0001553788) (Filer)

    2/6/26 8:13:57 AM ET
    $SBEV
    Beverages (Production/Distribution)
    Consumer Staples

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Biere Peter converted options into 18,567 shares and covered exercise/tax liability with 5,510 shares, increasing direct ownership by 17% to 90,332 units (SEC Form 4)

    4 - IZEA Worldwide, Inc. (0001495231) (Issuer)

    2/2/26 4:08:56 PM ET
    $IZEA
    Advertising
    Consumer Discretionary

    Chief Executive Officer Venetucci Patrick James converted options into 30,650 shares and covered exercise/tax liability with 10,256 shares, increasing direct ownership by 7% to 325,610 units (SEC Form 4)

    4 - IZEA Worldwide, Inc. (0001495231) (Issuer)

    2/2/26 4:07:29 PM ET
    $IZEA
    Advertising
    Consumer Discretionary

    New insider Caragol William J claimed no ownership of stock in the company (SEC Form 3)

    3 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/26/26 4:08:26 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Unilever PLC downgraded by Deutsche Bank

    Deutsche Bank downgraded Unilever PLC from Buy to Hold

    2/9/26 7:00:29 AM ET
    $UL
    Package Goods/Cosmetics
    Consumer Discretionary

    H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target

    H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00

    1/27/26 8:47:34 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

    Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the amended license agreement HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today announced that it has expanded its license agreement with Newsoara Biopharma Co. Ltd. ("Newsoara") to provid

    2/2/26 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    China SXT Pharmaceuticals, Inc. Announces Share Consolidation

    TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the o

    1/30/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)

    4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/20/26 10:29:36 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Donahue Kevin Michael bought $258,827,700,000 worth of shares (643,850 units at $402,000.00) (SEC Form 4)

    4 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/16/26 3:42:37 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gardner Lindsay A bought $2,000 worth of shares (500 units at $4.00), increasing direct ownership by 0.42% to 119,553 units (SEC Form 4)

    4 - IZEA Worldwide, Inc. (0001495231) (Issuer)

    8/29/25 4:00:54 PM ET
    $IZEA
    Advertising
    Consumer Discretionary

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

    HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1

    10/9/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

    BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection

    9/30/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oligomerix Elects New Chairman William Caple to Board of Directors

    Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer's diseases, today announced the election of William Caple as its new Chairman of the Board of Directors. "Oligomerix is extremely pleased to announce the election of Bill Caple as its new Chairman of the Board. Bill brings extensive experience to our Board with his broad and diverse business experience, especially in helping to secure corporate investment and accelerate organizations' business plans, which is precisely what Oligomerix needs at this stage of development," said Doug Durand, Oligomerix Board member. With over 30 years i

    9/3/25 8:30:00 AM ET
    $SBEV
    Beverages (Production/Distribution)
    Consumer Staples

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Financials

    Live finance-specific insights

    View All

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IZEA Extends Profitability Momentum in Q3 2025 with $8.1 Million in Revenue

    $8.8 Million Year-Over-Year Improvement in Net ResultsPositive Cash from Operations ORLANDO, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ:IZEA), a leading influencer marketing company that makes Creator Economy solutions for marketers, reported its financial and operational results for the third quarter ended September 30, 2025. Q3 2025 Financial Summary Compared to Q3 2024 Total revenue declined to $8.1 million, compared to $8.8 millionManaged Services revenue increased 5% to $8.0 million compared to $7.7 million (excluding Hoozu)Reflecting our strategy to shed non-recurring, unprofitable projects in favor of larger, recurring accounts, Managed Services bookings

    11/12/25 4:01:00 PM ET
    $IZEA
    Advertising
    Consumer Discretionary

    Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

    Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de

    11/12/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVGR
    $BBIG
    $CEI
    $CPOP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    11/14/24 3:23:30 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avinger Inc.

    SC 13G/A - Avinger Inc (0001506928) (Subject)

    11/13/24 11:13:40 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care